Project Grant K99NS141888
- Federal Grant Award Summary The University of Arizona received a $3.03 million Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded on September 30, 2025, with a completion date of September 29, 2029. Led by Principal Investigator Dr. Grilli, this research initiative focuses on developing and validating novel semantic memory assessment measures to detect early Alzheimer's disease (AD) pathology in cognitively unimpaired and mildly...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Leland Stanford Junior University a Project Grant of $122,526.00 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) on May 15, 2026, with completion targeted for April 30, 2028. This award funds research to delineate the mechanisms of Alzheimer's disease initiation and propagation using novel adult human brain organoids. The...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of Arizona $711,256 under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) for a five-year project running from June 1, 2026, through May 31, 2031. This Project Grant supports fundamental neuroscience research aimed at elucidating how neurons respond to and control Toxoplasma gondii infection in the central nervous...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of Arizona $1,165,710 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program on August 1, 2025, for a five-year project extending through June 30, 2030. This Project Grant supports research into the molecular mechanisms of pharmacological activation of small-conductance calcium-activated potassium (KCa2) channels, which...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded the University of South Florida $3.297 million under the Aging Research program (CFDA 93.866) for a four-year project period (September 1, 2025 – August 31, 2029) to develop novel peptidomimetic biomaterials that inhibit amyloid-beta (Aβ42) aggregation in Alzheimer's disease. The research deliverables include the rational design and characterization of structurally related analogues to a lead compound that stabilizes Aβ...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded a Project Grant of $458,622 to the Research Foundation For Mental Hygiene, Inc. (operating as the New York State Psychiatric Institute) under the Aging Research program (CFDA 93.866) effective March 1, 2026, with a completion date of February 29, 2028. The award funds research to elucidate the neuronal mechanisms of focused ultrasound-induced blood-brain barrier opening (FUS-BBBO) as a novel therapeutic intervention for...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $541,750 to San Diego Biomedical Research Institute on May 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This two-year project, concluding April 30, 2028, will deliver the discovery and validation of novel noncanonical autophagy modulators designed to treat Alzheimer's disease and related dementias, including...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded $310,083 to the University of Arizona under the Aging Research program (CFDA 93.866) for a two-year project period from September 1, 2025, through August 31, 2027. This Project Grant supports biomedical research investigating the role of TMEM106B (Transmembrane Protein 106B) and mitochondrial dysfunction in frontotemporal lobar degeneration (FTLD) and other age-related dementias. The research aims to elucidate...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded J. David Gladstone Institutes a Project Grant of $1,459,072 on August 1, 2025, under the Aging Research program (CFDA 93.866) to conduct research on Alzheimer's Disease (AD)-related neurological dysfunction. The research will deliver scientific knowledge and methodological innovations focused on understanding how inhibitory interneurons—specifically parvalbumin (PVALB) and somatostatin (SST) cell types—contribute...
- Federal Grant Award Summary The University of South Florida received a $3.33 million Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) awarded September 22, 2025, with completion targeted for May 31, 2030. The grant supports transcriptome-wide mapping of brain N6-methyladenosine (M6A) methylome in Alzheimer's disease. The research aims to develop novel technologies for comprehensive, base-resolution profiling of M6A modifications across the entire brain...
The University of Arizona received a $102,368 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective June 15, 2026 through May 31, 2028. The project investigates novel therapeutic approaches to unlock the brain's lymphatic system as a treatment modality for Alzheimer's disease and related dementias. The research focuses on characterizing brain lymphatic drainage using the TgF344-AD rat model and evaluating two repurposed therapies: manual lymphatic drainage (MLD)—a non-invasive light skin massage technique—and lymphaticovenous anastomosis (LVA), a first-line surgical intervention for lymphatic disease, both previously approved for lymphatic conditions but not yet studied for Alzheimer's disease applications. This research addresses a critical unmet need in Alzheimer's disease treatment, as current immunotherapies have limited efficacy, significant side effects, and accessibility constraints. The project builds on the hypothesis that impaired brain lymphatic clearance leads to toxic metabolite accumulation, including amyloid beta, which progresses to cognitive decline. By investigating therapies that enhance lymphatic function, the research aims to develop accessible treatment options that may improve cognition and reduce Alzheimer's-related biomarkers, potentially providing alternatives to existing costly interventions for the 6.9 million Americans over age 65 currently affected by the disease.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $102.4k | 6/12/26 |